Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Phathom Pharmaceuticals (PHAT) Inventory (2023 - 2025)

Phathom Pharmaceuticals (PHAT) has disclosed Inventory for 3 consecutive years, with $5.5 million as the latest value for Q4 2025.

  • On a quarterly basis, Inventory rose 72.01% to $5.5 million in Q4 2025 year-over-year; TTM through Dec 2025 was $5.5 million, a 72.01% increase, with the full-year FY2025 number at $5.5 million, up 72.01% from a year prior.
  • Inventory was $5.5 million for Q4 2025 at Phathom Pharmaceuticals, up from $3.6 million in the prior quarter.
  • In the past five years, Inventory ranged from a high of $5.5 million in Q4 2025 to a low of $111000.0 in Q2 2023.
  • A 3-year average of $2.3 million and a median of $2.2 million in 2024 define the central range for Inventory.
  • Peak YoY movement for Inventory: skyrocketed 1861.26% in 2024, then surged 57.6% in 2025.
  • Phathom Pharmaceuticals' Inventory stood at $1.2 million in 2023, then surged by 165.56% to $3.2 million in 2024, then skyrocketed by 72.01% to $5.5 million in 2025.
  • Per Business Quant, the three most recent readings for PHAT's Inventory are $5.5 million (Q4 2025), $3.6 million (Q3 2025), and $3.4 million (Q2 2025).